With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Alnylam Pharmaceuticals on Tuesday said its experimental drug lumasiran succeeded in a Phase 3 study of patients with an ultra-rare kidney disease, leading the biotech to plan regulatory submissions in the U.S. and Europe in early 2020 for the RNA interference-based medicine.